GlaxoSmithKline Plc has signed an agreement with a service company in Germany to gain access to technology for industrialising cell and gene therapies. The two parties will also discover new chimeric antigen-receptor T (CAR T) cell therapies.
Scientists at Michigan State University have described a new type of stem cell following laboratory experiments with mice. They say this could lead to new tools for studying birth defects and other reproductive problems.
The Swedish government announced on 3 March that it is asking a nominating committee to propose new board members for the Karolinska Institutet – the latest twist in a long-running investigation into the research and clinical activities of the visiting professor and surgeon Paolo Macchiarini.
Baxalta Inc has entered the gene editing field with an agreement to work with Precision BioSciences on cancer therapies using engineered immune cells. The collaboration was announced a little more than a month after Baxalta agreed to be acquired by Shire Plc in a deal valued at $32 billion.
A project aimed at improving the properties of adeno-associated viral (AAV) vectors for use in gene therapy has been launched in the UK by Cobra Biologics Ltd, a contract research group, and the Center for Process Innovation, a UK government funded entity.
UK-based Oxford BioMedica Plc is raising £8.1 million with a fully underwritten share placement to finance the expansion of its lentiviral vector manufacturing capacity and advance the clinical development of its gene therapy portfolio.
After discovering a way to produce insulin-producing beta cells from stem cells, US scientists have now shown that they can encapsulate these cells in an alginate and safely transplant them into mice. Moreover, the transplanted cells were shown to produce insulin and maintain blood glucose levels in the mice for 174 days.
A product that is currently used to treat burns has now been approved in the US for certain diabetic foot ulcers. It is a matrix which consists of silicone, cow collagen and shark cartilage and is placed over the ulcer providing an environment for new skin and tissue to regenerate and heal the wound.
An experimental gene therapy administered to a small group of elderly patients with wet age-related macular degeneration has been shown to be safe, and showed promise as a long-term treatment option for the disease, according to a paper in The Lancet.
A candidate gene therapy for haemophilia B developed by scientists at University College London (UCL) was so effective in a Phase 1/2 study that Syncona LLP has decided to start a new company to commercialise it.